Amgen (AMGN) stock is at an interesting point right now. If you bet on it, you are betting on a company that's growing reasonably, is sustaining good cash flow and margin, has a low-debt to market ...

Amgen Inc. upgraded to cautious Buy: pipeline growth drivers, margin upside, and risk/reward near lows. Click for this AMGN ...

Amgen (NASDAQ:AMGN) executives used a Jefferies investor conference appearance to emphasize the company’s first-quarter ...

Jefferies Global Healthcare Conference 2026 June 4, 2026 9:55 AM EDTCompany ParticipantsPeter Griffith - Executive VP & ...

More than 1 in 10 U.S. adults is currently taking a GLP-1 weight-loss drug. And these medicines are getting cheaper seemingly ...

In high-risk patients without prior heart attack or stroke who underwent percutaneous coronary intervention, evolocumab reduced risk for major adverse CV events compared with placebo, according to new ...

Rosie O’Donnell has said her physical transformation is “completely shocking” ...

As 2026 brings the first wave of Medicare drug price negotiations under the Inflation Reduction Act, the landscape for high-cost cardiovascular medications like Repatha (evolocumab) has shifted ...

Amgen AMGN stock has declined 12.6% in the past three months. Investors are increasingly worried about a mix of near-term revenue pressure, patent expirations, obesity-drug competition and uncertainty ...

Amgen Inc () has held its Q1 earnings call. Read on for the main highlights of the call. Meet Samuel – Your Personal Investing Prophet. Start a conversation with TipRanks’ tru ...

On the face of it, the battle between Amgen and Sanofi/Regeneron being heard in the US Supreme Court is a mundane biopharma contest over rights and royalties on PCSK9 inhibitor drugs – but its ...

Eli Lilly is laying the groundwork for a phase 2 trial of the lipid-lowering gene editor it acquired from Verve Therapeutics, with the candidate now showing strong and consistent cholesterol ...